NCT00739609 - IDO Inhibitor Study for Relapsed or Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions

Breast CancerLung CancerMelanomaPancreatic CancerSolid Tumors

Interventions

DRUG

1-methyl-D-tryptophan

D-1MT will be administered in escalating doses. Initial dosing will be 200 mg by mouth daily with escalation planned to 2000 mg by mouth daily and potentially higher doses in subsequent cohorts if tolerated and pharmacokinetic and biologic data support further dose escalation.

Trial Locations (1)

37232

Vanderbilt University, Nashville